SI2581389T1 - Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporaba - Google Patents
Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporabaInfo
- Publication number
- SI2581389T1 SI2581389T1 SI201130978A SI201130978A SI2581389T1 SI 2581389 T1 SI2581389 T1 SI 2581389T1 SI 201130978 A SI201130978 A SI 201130978A SI 201130978 A SI201130978 A SI 201130978A SI 2581389 T1 SI2581389 T1 SI 2581389T1
- Authority
- SI
- Slovenia
- Prior art keywords
- exendin
- analog
- preparation
- fusion protein
- fusion
- Prior art date
Links
- 108010011459 Exenatide Proteins 0.000 title 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 title 1
- 229960001519 exenatide Drugs 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010205166A CN101891823B (zh) | 2010-06-11 | 2010-06-11 | 一种Exendin-4及其类似物融合蛋白 |
| PCT/CN2011/075604 WO2011153965A1 (zh) | 2010-06-11 | 2011-06-10 | Exendin-4及其类似物的融合蛋白，其制备和应用 |
| EP11791955.5A EP2581389B1 (en) | 2010-06-11 | 2011-06-10 | Fusion protein of exendin-4 and its analog, preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2581389T1 true SI2581389T1 (sl) | 2017-01-31 |
Family
ID=43101193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130978A SI2581389T1 (sl) | 2010-06-11 | 2011-06-10 | Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporaba |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8889619B2 (sl) |
| EP (1) | EP2581389B1 (sl) |
| JP (1) | JP5865359B2 (sl) |
| KR (1) | KR101530065B1 (sl) |
| CN (1) | CN101891823B (sl) |
| BR (1) | BR112012029689B1 (sl) |
| EA (1) | EA023037B1 (sl) |
| ES (1) | ES2597962T3 (sl) |
| SI (1) | SI2581389T1 (sl) |
| WO (1) | WO2011153965A1 (sl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| CN102552883B (zh) * | 2010-12-09 | 2014-02-19 | 天津药物研究院 | 一种多肽复合物、药物组合物、其制备方法和应用 |
| CN102558362A (zh) * | 2012-02-17 | 2012-07-11 | 东莞金朗生物科技有限公司 | 一种用于治疗糖尿病的融合蛋白及其制备方法 |
| CN103130889A (zh) * | 2012-06-15 | 2013-06-05 | 中国药科大学 | 一种Exendin-4类似物及其制备方法和应用 |
| CN102827270A (zh) * | 2012-09-13 | 2012-12-19 | 无锡和邦生物科技有限公司 | 一种聚乙二醇化艾塞那肽衍生物及其用途 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| BR112015014510A2 (pt) | 2012-12-21 | 2017-11-21 | Sanofi Sa | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais |
| CN103204944B (zh) * | 2013-03-26 | 2014-05-28 | 江苏健德生物药业有限公司 | 用于治疗糖尿病的长效免疫融合蛋白 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN104558198A (zh) * | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| CN105801705B (zh) * | 2014-12-31 | 2019-05-24 | 天境生物科技(上海)有限公司 | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| CN105753963B (zh) * | 2016-04-13 | 2019-08-30 | 中国药科大学 | 高活性艾塞那肽类似物及其医药应用 |
| CN106046176B (zh) * | 2016-08-16 | 2019-09-10 | 中国药科大学 | 一种高活性长效降糖融合蛋白及其制备方法与医药用途 |
| AU2017371217B2 (en) * | 2016-12-09 | 2020-03-19 | Akston Biosciences Corporation | Insulin-Fc fusions and methods of use |
| US11820801B2 (en) | 2018-04-26 | 2023-11-21 | Good T Cells, Inc. | Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| LT4186920T (lt) | 2018-06-29 | 2024-04-25 | Akston Biosciences Corporation | Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai |
| BR112021008180A2 (pt) | 2018-10-30 | 2021-08-03 | Jianning Liu | polipeptídeo de glp-1 tendo atividade agonista de receptor glp-1 e uso do mesmo |
| CN109394681B (zh) * | 2018-11-06 | 2020-03-17 | 北京东方百泰生物科技有限公司 | 一种含有Exendin-4 Fc融合蛋白的注射制剂 |
| CN110151980B (zh) * | 2019-06-30 | 2022-12-09 | 中国药科大学 | Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用 |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| IL294051A (en) | 2019-12-19 | 2022-08-01 | Akston Biosciences Corp | Long-acting insulin-fc fusion proteins, and methods of use |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HRP20230990T1 (hr) | 2020-04-10 | 2023-12-08 | Akston Biosciences Corporation | Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| WO2023004406A2 (en) | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| CN113801853B (zh) * | 2021-11-19 | 2022-03-15 | 山东兴瑞生物科技有限公司 | Exendin-4融合基因修饰的MSC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| CA2500295A1 (en) * | 2002-10-02 | 2004-04-29 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| CN1802386B (zh) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
| EP1891106A2 (en) | 2005-05-05 | 2008-02-27 | Cadila Healthcare Ltd. | Novel compounds as glp-i agonists |
| CA2658673A1 (en) * | 2005-07-27 | 2008-02-01 | Gerald J. Prud'homme | Composition and method for prevention and treatment of type i and type ii diabetes |
| CN1935846A (zh) | 2005-09-14 | 2007-03-28 | 王庆华 | 一种用于治疗糖尿病的融合蛋白及其制备方法和应用 |
| JP5119932B2 (ja) * | 2008-01-11 | 2013-01-16 | ヤマハ株式会社 | 鍵盤楽器、ピアノおよび自動演奏ピアノ |
| CN101891823B (zh) * | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
-
2010
- 2010-06-11 CN CN201010205166A patent/CN101891823B/zh active Active
-
2011
- 2011-06-10 JP JP2013513541A patent/JP5865359B2/ja active Active
- 2011-06-10 US US13/635,236 patent/US8889619B2/en active Active
- 2011-06-10 WO PCT/CN2011/075604 patent/WO2011153965A1/zh active Application Filing
- 2011-06-10 ES ES11791955.5T patent/ES2597962T3/es active Active
- 2011-06-10 SI SI201130978A patent/SI2581389T1/sl unknown
- 2011-06-10 BR BR112012029689-2A patent/BR112012029689B1/pt active IP Right Grant
- 2011-06-10 EP EP11791955.5A patent/EP2581389B1/en active Active
- 2011-06-10 KR KR1020127024257A patent/KR101530065B1/ko active IP Right Grant
- 2011-06-10 EA EA201290722A patent/EA023037B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101891823A (zh) | 2010-11-24 |
| EP2581389A4 (en) | 2013-10-09 |
| WO2011153965A1 (zh) | 2011-12-15 |
| JP2013531488A (ja) | 2013-08-08 |
| CN101891823B (zh) | 2012-10-03 |
| EP2581389B1 (en) | 2016-07-20 |
| EA023037B1 (ru) | 2016-04-29 |
| EA201290722A1 (ru) | 2013-05-30 |
| BR112012029689B1 (pt) | 2021-12-14 |
| JP5865359B2 (ja) | 2016-02-17 |
| US20130142795A1 (en) | 2013-06-06 |
| ES2597962T3 (es) | 2017-01-24 |
| KR101530065B1 (ko) | 2015-06-18 |
| US8889619B2 (en) | 2014-11-18 |
| EP2581389A1 (en) | 2013-04-17 |
| BR112012029689A2 (pt) | 2019-10-15 |
| KR20120127729A (ko) | 2012-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2581389T1 (sl) | Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporaba | |
| HK1253887A1 (zh) | 因子viii-fc嵌合多肽和雜交多肽及其使用方法 | |
| HK1223835A1 (zh) | 濃縮蛋白製劑及其用途 | |
| ZA201206832B (en) | Novel peptides and method for their preparation and use | |
| EP2714065A4 (en) | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, PROCESS FOR THEIR MANUFACTURE AND USE | |
| IL229753A0 (en) | Proteins that release relaxin and their use | |
| LT3040424T (lt) | Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai | |
| EP2651964A4 (en) | NETWORKED PEPTIDES AND PROTEINS, METHOD FOR THEIR PREPARATION AND USES THEREOF | |
| IL229723A0 (en) | Human fusion proteins including interferons and modified targeted ubiquitin proteins | |
| EP2657188A4 (en) | FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME | |
| EP2711376A4 (en) | FGFR-FC FUSION PROTEIN AND USE THEREOF | |
| EP3029072A4 (en) | Glp-1 analog fusion protein and preparation method and use thereof | |
| IL218474A (en) | Fusion proteins and their method of production | |
| EP2700654A4 (en) | HUMAN INSULIN AND ANALOG CONJUGATE THEREOF | |
| EP2655410A4 (en) | ANTI-INFLAMMATORY PROTEINS AND METHODS OF PREPARATION AND USE THEREOF | |
| PT3210990T (pt) | Levoisovalerilespiramicina iii e as suas preparações, processos para a sua preparação e as suas utilizações | |
| HUP0900319A2 (en) | New peptides, method of producing therof and use thereof | |
| EP2563817A4 (en) | FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE | |
| ZA201209566B (en) | Novel glucagon like peptide analogs,composition,and method of use | |
| EP2610349A4 (en) | FULL-PIPES, PREPARATION AND USE | |
| EP2634184A4 (en) | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | |
| GB2488494B (en) | Solution, use and method of preparation thereof | |
| GB2503802B (en) | Caspofungin analog, and Preparation Method and Uses thereof | |
| ZA201209021B (en) | Therapeutic peptide composition and method | |
| AU2011902431A0 (en) | Fusion Proteins and Use Thereof |